Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2018

01-06-2018 | Original Article

Quasispecies characters of hepatitis B virus in immunoprophylaxis failure infants

Authors: Xin Wang, Wanyan Deng, Keli Qian, Haijun Deng, Yong Huang, Zeng Tu, Ailong Huang, Quanxin Long

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2018

Login to get access

Abstract

Hepatitis B vaccination prevents 80–95% of transmission and reduces the incidence of HBV in children. The variations in the a determinant of HBV surface antigen (HBsAg) have been reported to be the most prevalent cause for vaccine or antibody escape. There is a conflicting evidence on as to whether escape mutants arise de novo in infected infants or whether the mutants, that have preexisted maternally, subsequently undergo selective replication in the infant under immune pressure. Here, we report that nearly 65% (55 of 85) vaccination failure in child patients has no amino acid substitution in a determinant as seen by Sanger sequencing. We further employed an Illumina sequencing platform-based method to detect HBV quasispecies in four immunoprophylaxis failure infants and their mothers. In our data, the substitution rate of amino acid located at a determinant is relatively low (< 10%), I/T126A, C124S, F134Y, K141Q, Q129H, D144A, G145V, and N146K, which showed no statistical difference to their mothers, proving that these vaccine escape mutants preexist maternally as minor variants. Besides that, bioinformatical analysis showed that the binding affinity of high variation epitopes (amino acid divergence in mother and their infants > 20%) to related HLA molecules was generally decreased, these traces of immune escape suggesting that immune pressure was present and was effective in all samples.
Appendix
Available only for authorised users
Literature
2.
go back to reference Peveling-Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S, Hofmann WP (2013) Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat 20(4):234–239CrossRefPubMed Peveling-Oberhag J, Herrmann E, Kronenberger B, Farnik H, Susser S, Sarrazin C, Zeuzem S, Hofmann WP (2013) Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat 20(4):234–239CrossRefPubMed
3.
go back to reference Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM (2013) Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology Rodriguez C, Chevaliez S, Bensadoun P, Pawlotsky JM (2013) Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing. Hepatology
4.
go back to reference Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, Cui HC, Yan YP (2011) Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol 83(5):791–795CrossRefPubMed Shao ZJ, Zhang L, Xu JQ, Xu DZ, Men K, Zhang JX, Cui HC, Yan YP (2011) Mother-to-infant transmission of hepatitis B virus: a Chinese experience. J Med Virol 83(5):791–795CrossRefPubMed
5.
go back to reference Chen DS (2009) Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 50(4):805–816CrossRefPubMed Chen DS (2009) Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 50(4):805–816CrossRefPubMed
6.
go back to reference Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL (1999) Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30(5):1312–1317CrossRefPubMed Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL (1999) Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology 30(5):1312–1317CrossRefPubMed
7.
go back to reference Ni YH (2011) Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol 46(1):1–8CrossRefPubMed Ni YH (2011) Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol 46(1):1–8CrossRefPubMed
8.
go back to reference Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M (1994) Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68(4):2671–2676PubMedPubMedCentral Yamamoto K, Horikita M, Tsuda F, Itoh K, Akahane Y, Yotsumoto S, Okamoto H, Miyakawa Y, Mayumi M (1994) Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol 68(4):2671–2676PubMedPubMedCentral
9.
go back to reference Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R (1995) Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 345(8962):1406–1407CrossRefPubMed Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R (1995) Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet 345(8962):1406–1407CrossRefPubMed
10.
go back to reference Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, Zhang Y, Bi S (2013) Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol 87(22):12196–12206CrossRefPubMedPubMedCentral Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, Zhang Y, Bi S (2013) Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol 87(22):12196–12206CrossRefPubMedPubMedCentral
11.
go back to reference Hsu HY, Chang MH, Ni YH, Chen HL (2004) Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53(10):1499–1503CrossRefPubMedPubMedCentral Hsu HY, Chang MH, Ni YH, Chen HL (2004) Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut 53(10):1499–1503CrossRefPubMedPubMedCentral
12.
go back to reference Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR (2008) A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 13(2):161–175PubMed Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR (2008) A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther 13(2):161–175PubMed
13.
go back to reference Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152(1):163–175PubMed Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152(1):163–175PubMed
14.
go back to reference Liu F, Yu DM, Huang SY, Yu JL, Zhang DH, Gong QM, Zhang XX (2014) Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection. J Clin Microbiol 52(5):1556–1565CrossRefPubMedPubMedCentral Liu F, Yu DM, Huang SY, Yu JL, Zhang DH, Gong QM, Zhang XX (2014) Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection. J Clin Microbiol 52(5):1556–1565CrossRefPubMedPubMedCentral
15.
go back to reference Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17(8):1195–1201CrossRefPubMedPubMedCentral Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17(8):1195–1201CrossRefPubMedPubMedCentral
16.
go back to reference Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL (2012) A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One 7(9):e46334CrossRefPubMedPubMedCentral Kagan RM, Johnson EP, Siaw M, Biswas P, Chapman DS, Su Z, Platt JL, Pesano RL (2012) A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One 7(9):e46334CrossRefPubMedPubMedCentral
17.
go back to reference Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, Fuller C, Daumer M, Teuber G, Wedemeyer H et al (2013) Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 87(11):6172–6181CrossRefPubMedPubMedCentral Dietz J, Schelhorn SE, Fitting D, Mihm U, Susser S, Welker MW, Fuller C, Daumer M, Teuber G, Wedemeyer H et al (2013) Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 87(11):6172–6181CrossRefPubMedPubMedCentral
18.
go back to reference Torresi J (2002) The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25(2):97–106CrossRefPubMed Torresi J (2002) The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol 25(2):97–106CrossRefPubMed
19.
go back to reference Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS (1998) Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27(1):213–222CrossRefPubMed Ghany MG, Ayola B, Villamil FG, Gish RG, Rojter S, Vierling JM, Lok AS (1998) Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 27(1):213–222CrossRefPubMed
20.
go back to reference Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A et al (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5(5):e1000414CrossRefPubMedPubMedCentral Wood N, Bhattacharya T, Keele BF, Giorgi E, Liu M, Gaschen B, Daniels M, Ferrari G, Haynes BF, McMichael A et al (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 5(5):e1000414CrossRefPubMedPubMedCentral
21.
go back to reference Zhang L, Gui XE, Teter C, Zhong H, Pang Z, Ding L, Li F, Zhou Y (2014) Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. Vaccine 32(46):6091–6097CrossRefPubMed Zhang L, Gui XE, Teter C, Zhong H, Pang Z, Ding L, Li F, Zhou Y (2014) Effects of hepatitis B immunization on prevention of mother-to-infant transmission of hepatitis B virus and on the immune response of infants towards hepatitis B vaccine. Vaccine 32(46):6091–6097CrossRefPubMed
22.
go back to reference Duan Z, Chen X, Liang Z, Zeng Y, Zhu F, Long L, McCrae MA, Zhuang H, Shen T, Lu F (2014) Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine 32(41):5316–5322CrossRefPubMed Duan Z, Chen X, Liang Z, Zeng Y, Zhu F, Long L, McCrae MA, Zhuang H, Shen T, Lu F (2014) Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine 32(41):5316–5322CrossRefPubMed
23.
go back to reference Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL (2015) Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology 61(4):1183–1191CrossRefPubMed Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL (2015) Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology 61(4):1183–1191CrossRefPubMed
24.
go back to reference Carman WF (1997) The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4(Suppl 1):11–20CrossRefPubMed Carman WF (1997) The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4(Suppl 1):11–20CrossRefPubMed
25.
go back to reference Ngui SL, O'Connell S, Eglin RP, Heptonstall J, Teo CG (1997) Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 176(5):1360–1365CrossRefPubMed Ngui SL, O'Connell S, Eglin RP, Heptonstall J, Teo CG (1997) Low detection rate and maternal provenance of hepatitis B virus S gene mutants in cases of failed postnatal immunoprophylaxis in England and Wales. J Infect Dis 176(5):1360–1365CrossRefPubMed
26.
go back to reference Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS (2002) Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 68(3):319–327CrossRefPubMed Nainan OV, Khristova ML, Byun K, Xia G, Taylor PE, Stevens CE, Margolis HS (2002) Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 68(3):319–327CrossRefPubMed
27.
go back to reference Fuller CW, Middendorf LR, Benner SA, Church GM, Harris T, Huang X, Jovanovich SB, Nelson JR, Schloss JA, Schwartz DC et al (2009) The challenges of sequencing by synthesis. Nat Biotechnol 27(11):1013–1023CrossRefPubMed Fuller CW, Middendorf LR, Benner SA, Church GM, Harris T, Huang X, Jovanovich SB, Nelson JR, Schloss JA, Schwartz DC et al (2009) The challenges of sequencing by synthesis. Nat Biotechnol 27(11):1013–1023CrossRefPubMed
28.
go back to reference Wang YQ, Ren YF, Song YJ, Xue YF, Zhang XJ, Cao ST, Deng ZJ, Wu J, Chen L, Li G et al (2014) MicroRNA-581 promotes hepatitis B virus surface antigen expression by targeting Dicer and EDEM1. Carcinogenesis 35(9):2127–2133CrossRefPubMed Wang YQ, Ren YF, Song YJ, Xue YF, Zhang XJ, Cao ST, Deng ZJ, Wu J, Chen L, Li G et al (2014) MicroRNA-581 promotes hepatitis B virus surface antigen expression by targeting Dicer and EDEM1. Carcinogenesis 35(9):2127–2133CrossRefPubMed
29.
go back to reference Kim D, Lyoo KS, Smith D, Hur W, Hong SW, Sung PS, Yoon SK, Mehta S (2011) Number of mutations within CTL-defined epitopes of the hepatitis B virus (HBV) core region is associated with HBV disease progression. J Med Virol 83(12):2082–2087CrossRefPubMed Kim D, Lyoo KS, Smith D, Hur W, Hong SW, Sung PS, Yoon SK, Mehta S (2011) Number of mutations within CTL-defined epitopes of the hepatitis B virus (HBV) core region is associated with HBV disease progression. J Med Virol 83(12):2082–2087CrossRefPubMed
30.
go back to reference Mishra A, Rao KV, Durgapal H, Manivel V, Panda SK (1993) Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen. Immunology 79(3):362–367PubMedPubMedCentral Mishra A, Rao KV, Durgapal H, Manivel V, Panda SK (1993) Human T-helper cell responses to a synthetic peptide derived from the hepatitis B surface antigen. Immunology 79(3):362–367PubMedPubMedCentral
31.
go back to reference Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S et al (2012) Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 8(3):e1002529CrossRefPubMedPubMedCentral Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, Berlin AM, Malboeuf CM, Ryan EM, Gnerre S et al (2012) Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 8(3):e1002529CrossRefPubMedPubMedCentral
32.
go back to reference Mizukoshi E, Sidney J, Livingston B, Ghany M, Hoofnagle JH, Sette A, Rehermann B (2004) Cellular immune responses to the hepatitis B virus polymerase. J Immunol 173(9):5863–5871CrossRefPubMed Mizukoshi E, Sidney J, Livingston B, Ghany M, Hoofnagle JH, Sette A, Rehermann B (2004) Cellular immune responses to the hepatitis B virus polymerase. J Immunol 173(9):5863–5871CrossRefPubMed
Metadata
Title
Quasispecies characters of hepatitis B virus in immunoprophylaxis failure infants
Authors
Xin Wang
Wanyan Deng
Keli Qian
Haijun Deng
Yong Huang
Zeng Tu
Ailong Huang
Quanxin Long
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2018
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3235-5

Other articles of this Issue 6/2018

European Journal of Clinical Microbiology & Infectious Diseases 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.